Navigation Links
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
Date:3/23/2009

rtnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:  Jack Lief                                   Mary Claire Duch
               President and CEO                           WeissComm Partners
                                                           Media Relations
               David Walsey                                212.301.7228
               Senior Director, Corporate Communications

               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LONDON , Sept. 17, 2014 The global ... Tons by 2019. Squalene is a natural skin-identical chemical that ... & personal care, food supplements, pharmaceuticals, and in other applications ... The squalene market has a few major players and is ... (U.S.), Kishimoto Special Liver Oil Co. Ltd. ( Japan ...
(Date:9/17/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ... patent protected regenerative biomaterials and bioimplants processed from ... peer-reviewed clinical study.    The study ... Clinical Trial Evaluating the Use of ... Compression Therapy vs. Multi-layer Compression Therapy Alone in ...
(Date:9/17/2014)... Terracon Corporation has announced the introduction ... . This addition to the company’s industry-leading line ... polyethylene and available in 125 or 250 gallon capacities. ... two weeks or less. , The new pre-engineered TerraPure ... Terracon’s existing TerraPure tank line – plus quick turnaround. ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
Breaking Biology Technology:Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
... a leading global,full-service contract research organization, announced it ... Clinical Pharmacology., Dr. Wei joins Medpace with ... early phase cardio-metabolic studies. He will consult,with sponsors ... to which studies merit inclusion in the programs ...
... today announced that it has appointed Mr. Jorge,Cantonnet to ... effective as of 1 February 2008. Mr. Cantonnet is ... agro-biotechnology company listed on OTCBB in Dec 2007,(OTC Bulletin ... million in fiscal year ended 30 September 2007, with ...
... and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX ... drugs for infectious,diseases, will add a 600mg celgosivir ... viral kinetics study in hepatitis C virus,("HCV") treatment-naive ... Health Canada and Institutional Review Board (IRB) approvals. ...
Cached Biology Technology:Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD 2China Agro-Technology Appoints New CEO 2China Agro-Technology Appoints New CEO 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6
(Date:9/16/2014)... Columbia Center for Children,s Environmental Health at the Mailman ... an association between childhood asthma and prenatal exposure to ... products. Results appear online in the journal Environmental ... exposed during pregnancy to higher levels of the chemicals, ... 72 percent and 78 percent increase in risk of ...
(Date:9/16/2014)... 17, 2014)The North American Menopause Society (NAMS) has ... care of midlife womenon everything from hot flashes ... American Menopause Society Recommendations for Clinical Care of ... Society,s journal Menopause . This is the ... care of midlife women freely available to all ...
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... Suppressing a cellular cleanup-mechanism known as autophagy can ... neural degeneration. In an upcoming issue of Autophagy, scientists ... the first time that the opposite is true as ... flies prevented the age-dependent accumulation of cellular damage in ...
... lifeless lakeshore lapped by waves, floating algae learned to survive ... the Earth into a green paradise. The secrets of ... to the sequencing of a modern descendent of these first ... on recently exposed shorelines, quickly fruits, and then dies. ...
... collection of genes the genome of a ... link between single-celled algae and flowering plants. Just ... understand human genomic history, the sequencing of plant genomes ... kingdom, according to Ralph S. Quatrano, Ph.D., the Spencer ...
Cached Biology News:Aging gracefully requires taking out the trash 2Aging gracefully requires taking out the trash 3Moss genome shows how plants invaded the land and learned to survive heat and drought 2Moss genome shows how plants invaded the land and learned to survive heat and drought 3WUSTL researchers spearhead key genome initiative 2WUSTL researchers spearhead key genome initiative 3WUSTL researchers spearhead key genome initiative 4
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: